Treatment for Prostate Cancer

1
Effectiveness
1
Safety
Mile Square Health Center, Chicago, IL
Prostate Cancer+2 More
Eligibility
18+
All Sexes
Eligible conditions
Prostate Cancer

Study Summary

Smart Prostate Specific Antigen (PSA) Screening Study

See full description

Eligible Conditions

  • Prostate Cancer
  • Prostatic Neoplasms
  • PSA

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 16 primary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Monthly for 12 months during intervention.

12 months after intervention
Benefit and harm analysis during the intervention
Number of PCPs that have confidence in discussing prostate issues during the the intervention
Number of Urology referrals during the intervention
Number of patients referred to specialty care through patient navigation/ care coordination during the intervention
Number of prostate biopsy complications during the intervention
Month 12
Number of prostate biopsies performed using the risk levels of the National Comprehensive Cancer Network (NCCN) of very low, Favorable intermittent, Unfavorable intermittent, High, very high during the intervention
Month 12
Benefit and harm analysis 12 months prior to the intervention
Number of PCPs that have confidence in discussing prostate issues 12 months prior to the intervention
Number of Urology referrals 12 months prior to the intervention
Number of patients referred to specialty care 12 months prior to patient navigation/ care coordination
Number of prostate biopsy complications 12 months prior to the intervention
Month 12
Number of prostate biopsies performed using the risk levels of the National Comprehensive Cancer Network (NCCN) of very low, Favorable intermittent, Unfavorable intermittent, High, very high 12 months prior to the intervention
Month 12
Number of PSA tests ordered per number of clinical encounters during the intervention
PSA levels categorized as <4.0, 4.0-10.0 and >10.0 during the intervention
Month 12
Number of PSA levels categorized as <4.0, 4.0-10.0 and >10.0 12 month prior to the intervention
Number of PSA tests ordered per number of clinical encounters 12 months prior to the intervention

Trial Safety

Safety Estimate

1 of 3

Trial Design

1 Treatment Groups

Control

This trial requires 4600 total participants across 1 different treatment groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months after intervention
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 12 months after intervention for reporting.

Who is running the study

Principal Investigator
P. G.
Peter Gann, Principal Investigator
University of Illinois at Chicago

Closest Location

Mile Square Health Center - Chicago, IL

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There is one eligibility criterion to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
PCP employed by MSHC who provides care for male adult patients

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can prostate cancer be cured?

Add answer

A total of 6 % of patients were alive 15 years or more after radical prostatectomy. Withdrawal of adjuvant therapy was associated with survival rate. A significant difference was also noticed in the number of positive positive surgical margins (> or = 15%) and in number of positive lymph nodes (N+) with survival (p = 0.004). Despite the small numbers, all three indicators were associated with an adverse outcome.

Unverified Answer

What are the signs of prostate cancer?

Add answer

A history of exposure to PSA testing, elevated prostate specific antigen, a first-degree relative with prostate cancer, an enlarged prostate, black race, and a high-grade biopsy Gleason score are all independent risk factors for prostate cancer. The only significant risk factor that was not observed in this study was diabetes. Prostate specific antigen has proved a valid measure for screening high-risk men.

Unverified Answer

What is prostate cancer?

Add answer

There is considerable scope for the incorporation of PET scans and MRI examinations into the diagnostic work-up for the surveillance of prostate cancer. These would improve the prediction of the risk of disease in the localised and metastatic stages.

Unverified Answer

How many people get prostate cancer a year in the United States?

Add answer

Prostate cancer was rare in U.S. Hispanics and blacks and equally common among both in whites and Asians. Data from a recent study demonstrate the need for an improved system of prostate cancer control in the United States for all racial and ethnic groups.

Unverified Answer

What are common treatments for prostate cancer?

Add answer

Some prostate cancers are slow in progression and can require lifelong monitoring to detect a recurrence as early as possible. Treatment options and risks of certain treatments are described along with recommendations by urologist specialists.

Unverified Answer

What causes prostate cancer?

Add answer

There is a large gap in cancer prevention research for prostate cancer. Many of the currently recognized risk factors for prostate cancer are not related directly to how cancer develops. Identifying risk factors is particularly important for developing high-quality guidelines for and evaluating preventive strategies against prostate cancer.

Unverified Answer

Have there been any new discoveries for treating prostate cancer?

Add answer

Prostate cancer is a serious disease that is associated with prolonged survival. Most of the drugs that have had any significant activity in prostate cancer to date have been cytostatic or cytotoxic rather than cytotoxic, which are anti-angiogenesis (via the blockade of VEGF and/or VEGFR1) and anti-metalloproteinase/anti-metallothionein (via the inhibition of these target enzymes) respectively. However, anti-angiogenic therapy has been an integral component in the treatment of metastatic disease.

Unverified Answer

What does treatment usually treat?

Add answer

Patients with low-grade prostate cancers may not usually benefit on a treatment approach based on the known clinical, biological, and pathological criteria, and most of their treatments are ineffective. Although early detection of prostate cancer, and early detection of progression to high-grade prostate cancer are important, this will lead to patient mortality from prostate cancer with the most aggressive and the most life-threatening treatment regimens.

Unverified Answer

Has treatment proven to be more effective than a placebo?

Add answer

There are many studies assessing the effectiveness of alternative drugs compared with a placebo. These reports have many methodological difficulties in relation to the design, analysis and interpretation of these studies. The lack of a placebo option in clinical trials make comparisons between the various medicines difficult to perform, or even impossible. In the absence of adequate placebo-controlled trials, clinicians must use their knowledge of patient and disease features to decide whether new medicines should be used or existing medicines will be improved.

Unverified Answer

What is the latest research for prostate cancer?

Add answer

The advancement of our understanding of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) has been rapid due to the vast amount of new research available each year. Researchers are exploring genetic mutations, genetic diseases, cytokines, proteins and their interactions with the prostate. The list of new research is growing exponentially each year, and we should expect new options for prostate cancer treatment and prevention in the near future. In addition, it is important for us to remember that prostate cancer treatments are not equally efficient from person to person.

Unverified Answer

Is treatment safe for people?

Add answer

This exploratory study suggests that cancer in the contralateral mammary gland and/or prostate may occur in men treated with radiotherapy for high-dose prostate brachytherapy. Additional clinical study is required to clarify the clinical significance of this finding.

Unverified Answer

What are the common side effects of treatment?

Add answer

The most common adverse events associated with treatment with a GnRH antagonist were hot flashes, gynecomastia and weight gain. Some of these side effects were dose-dependent, in which the magnitude was related to the reduction in testosterone. These side effects, although most often manageable, could be important to remind the patients to notify their oncologist before starting treatment.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.